Clinical Trial of CNS-targeted HAART (CIT2)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

February 29, 2012

Study Completion Date

June 30, 2012

Conditions
HIV Infections
Interventions
DRUG

FDA Approved Antiretroviral Therapy (see list below)

"Combinations of FDA approved antiretroviral agents:~Atripla, Combivir, Emtriva, Epivir, Epzicom, Retrovir, Trizivir, Truvada, Viread, Ziagen, Intelence, Rescriptor, Sustiva, Viramune, Agenerase, Aptivus, Invirase, Kaletra, Lexiva, Norvir, Prezista, Reyataz, Viracept, Fuzeon, Selzentry, Isentress~Generic names: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine, Emtricitabine/Tenofovir, Tenofovir, Abacavir, Etravirine, Delavirdine, Efavirenz, Nevirapine, Amprenavir, Tipranavir, Saquinavir, Lopinavir/ritonavir, Fosamprenavir, Ritonavir, Darunavir, Atazanavir, Nelfinavir, Enfuvirtide, Maraviroc, Raltegravir"

Trial Locations (5)

10024

Mount Sinai Medical Center, New York

21287

Johns Hopkins University- School of Medicine, Baltimore

63110

Washington University, St Louis

92103

HIV Neurobehavioral Research Center, University of California San Diego, San Diego

94110

University of California, San Francisco, San Francisco

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Institute of Mental Health (NIMH)

NIH

lead

University of California, San Diego

OTHER

NCT00624195 - Clinical Trial of CNS-targeted HAART (CIT2) | Biotech Hunter | Biotech Hunter